SynthesisVirology journal2011
Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
Synthesis in Virology journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- KASL clinical practice guidelines: management of chronic hepatitis B.Clinical and molecular hepatology · 2016Guideline
- Measures to reduce mother-to-child transmission of Hepatitis B virus in China: a meta-analysis.Digestive diseases and sciences · 2014Pooled it
- Pooled it
- Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.World journal of gastroenterology · 2012Pooled it
- Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy.Hepatology international · 2021Article
- An Overview of the Current Hepatitis B Treatment Strategies after Liver Transplantation.Middle East journal of digestive diseases · 2021Review
- Hepatitis B infection and risk factors among children living with HIV in Yaounde, Cameroon: an integrated management.BMC pediatrics · 2019Article
- Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study.Infection and drug resistance · 2019Article
- Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety.International journal of medical sciences · 2019Article
- Interleukin-1 receptor antagonist expression is inversely associated with outcomes of hepatitis B-related acute-on-chronic liver failure.Experimental and therapeutic medicine · 2017Article
- LHBs can elevate the expression of MDR1 through HIF-1α in patients with CHB infection: a comparative proteomic study.Oncotarget · 2017Article
- Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management.World journal of gastroenterology · 2015Review
- Detection and analysis of resistance mutations of hepatitis B virus.International journal of clinical and experimental medicine · 2015Article
- Entecavir Interacts with Influx Transporters hOAT1, hCNT2, hCNT3, but Not with hOCT2: The Potential for Renal Transporter-Mediated Cytotoxicity and Drug-Drug Interactions.Frontiers in pharmacology · 2015Article
- Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.Clinical and molecular hepatology · 2014Article
- A case report of de novo hepatocellular carcinoma after living donor liver transplantation.World journal of surgical oncology · 2013Article
- HIV/HBV coinfection in children and antiviral therapy.Expert review of anti-infective therapy · 2013Review
- Binding sensitivity of adefovir to the polymerase from different genotypes of HBV: molecular modeling, docking and dynamics simulation studies.Acta pharmacologica Sinica · 2013Article
- Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B.Drug design, development and therapy · 2013Review
- Efficacy of 3 years of adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance.World journal of hepatology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic hepatitis B virus (HBV) infection represents a serious global health problem and resistance to lamivudine (LAM) has become a serious clinical challenge. Previous rescue therapy for the treatment of chronic LAM-resistant hepatitis B infected patients included switching to entecavir (ETV) and adding adefovir (ADV) or tenofovir (TFV). At present, switching to ETV is not recommended for rescue therapy for LAM-resistant chronic hepatitis B (CHB). The aim of this report was to determine whether add-on ADV was a superior rescue strategy in the treatment of CHB patients with LAM resistance.
methodsWe searched Medline/PubMed, EMBASE, Web of Knowledge, and the Cochrane Library. Relative risks (RRs) of virologic response, virologic breakthrough, normalization of serum alanine aminotransferase (ALT) levels and HBeAg seroconversion rates were studied. Factors predicting virologic response, standardized mean differences (SMD) in HBV DNA levels and safety were reviewed.
resultsSix eligible trials (451 patients in total) were included in the analysis. The rate of virologic breakthrough in the ETV group was higher than that in the LAM plus ADV group. There were no statistical differences in virologic response, ALT normalization and HBeAg seroconversion in either group 48 weeks post treatment. LAM plus ADV combination therapy produced faster and greater HBV DNA reduction rates 24 weeks post therapy compared to ETV monotherapy. HBV DNA baseline levels and the initial virologic response (IVR) were predictive of the virologic response. Additionally, combination therapy or monotherapy were both well tolerated.
conclusionsLAM plus ADV combination therapy was more effective and produced longer-lasting effects than switching to ETV monotherapy in treating CHB patients with LAM resistance. However, considering the practical benefits and limitations of ADV, individualized therapy will be needed in patients with prior history of LAM resistant infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.